Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Acadia Pharmaceuticals

- PMLiVE

Charity coalition pledges millions for brain disease research

Will invest £30m developing candidates for neurodegenerative conditions

- PMLiVE

Online Parkinson’s platform could revolutionise chronic disease care

ParkinsonNet connects patients with doctors in a virtual setting

Roche - Basel

Roche signs Parkinson’s deal with Prothena

Antibody development agreement is worth up to $600m

- PMLiVE

Michael J Fox Foundation backs Lundbeck projects

Will fund Parkinson’s disease research

Biogen Idec building

Biogen Idec to develop Parkinson’s drugs with Amicus

Companies will develop treatments to target genetic mutation

- PMLiVE

Merck & Co drops Parkinson’s prospect preladenant

No better than placebo during phase III trial

- PMLiVE

Chasing the cure for Parkinson’s disease

Research for this common neurodegenerative disease has made remarkable progress over the last decade, but current therapies can only reduce its symptoms

- PMLiVE

GSK and Impax end Parkinson’s collaboration

Regulatory delays for IPX066 lead to split

Online Parkinson’s community launched

Britannia Pharmaceuticals' initiative focuses on mid- to late-stages of the disease

- PMLiVE

Phytopharm shares dive as Parkinson’s drug fails

Stock falls 80 per cent after Cogane failure in phase II

EISAI

Eisai forms neurology partnership with UCL

Unique ‘therapeutic innovation group’ will research Alzheimer's, Parkinson's and other brain conditions

- PMLiVE

Acadia shares increase as pimavanserin clears phase III trial

Demonstrated to reduce psychotic symptoms

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links